Related Experiment Video
Updated: Jul 15, 2026

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory
Helen O McCarthy1, Jonathan A Coulter, Jenny Worthington
1School of Pharmacy, McClay Research Centre, Queen's University, Lisburn Road, Belfast, Northern Ireland, UK. h.mccarthy@qub.ac.uk
Background:
Gene therapy has been identified as a promising treatment strategy for hormone refractory prostate cancer (HRPC). We report, for the first time, the use of the human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in HRPC.
Methods:
Human prostate carcinoma cells (PC3, DU145, LNCaP), colon cancer cells (HT29) and human microvascular endothelial cells (HMEC-1) were transfected in vitro with constitutively driven CMV/iNOS or hOC/iNOS plasmid DNA by cationic lipid vector. End points of these experiments were Western blotting, NO(.) generation using the Greiss test to measure accumulated nitrite, and clonogenic assay.
Results:
Transfection of the hOC/iNOS plasmid increased iNOS protein and total nitrite levels in PC3 and DU145 cells, but not LNCaP or HT29. Transfection with CMV/iNOS or hOC/iNOS resulted in no additional cytotoxicity in androgen-dependent LNCaP cells or in the non-prostate cell lines. However, transfection with either construct resulted in a greatly reduced cell survival (to 10-20%) in the androgen-independent PC3 and DU145 cell lines.
Conclusions:
Utilising the tumour-type specific properties of the hOC promoter in tandem with the iNOS gene, we have demonstrated target cell specificity, and transgene activation, in the androgen-independent prostate cancer cell lines (PC3 and DU145), an effect absent in normal and androgen-dependent cells. Furthermore, the levels of NO(.) generated are comparable with those seen generated with constitutively (CMV)-driven iNOS. The data obtained from this study provide a basis for future development of hOC/iNOS gene therapy.
Insights
This study introduces a novel gene therapy approach for hormone refractory prostate cancer using the human osteocalcin promoter to control nitric oxide synthase expression. The therapy demonstrated targeted cell specificity and reduced cancer cell survival in androgen-independent prostate cancer cells.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Gene therapy is a promising strategy for hormone refractory prostate cancer (HRPC).
- The human osteocalcin (hOC) promoter was investigated for controlling transgene expression.
- Inducible nitric oxide synthase (iNOS) is a target for cancer therapy.
Purpose of the Study:
- To evaluate the efficacy of the hOC promoter for inducible nitric oxide synthase (iNOS) gene therapy in HRPC.
- To assess the target cell specificity and cytotoxicity of hOC/iNOS in prostate cancer models.
- To compare hOC/iNOS with constitutively driven iNOS expression.
Main Methods:
- Human prostate cancer cell lines (PC3, DU145, LNCaP) and control cells were transfected with hOC/iNOS or CMV/iNOS plasmids.
- Transfection was achieved using a cationic lipid vector.
- Assays included Western blotting, Greiss test for nitrite measurement, and clonogenic assays.
Main Results:
- hOC/iNOS transfection increased iNOS protein and nitrite levels in androgen-independent PC3 and DU145 cells.
- No significant cytotoxicity was observed in androgen-dependent LNCaP cells or non-prostate cell lines.
- Cell survival was significantly reduced (to 10-20%) in PC3 and DU145 cells with both hOC/iNOS and CMV/iNOS.
Conclusions:
- The hOC promoter enables tumor-type specific transgene activation of iNOS in androgen-independent prostate cancer cells.
- Nitric oxide generation with hOC/iNOS is comparable to constitutively driven iNOS.
- This study provides a foundation for developing hOC/iNOS gene therapy for HRPC.
Related Concept Videos
Nitric Oxide Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Mechanism of Angiogenesis
Regulation of Hormone Secretion
Humoral stimuli,...
Paracrine Signaling
